HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.

AbstractBACKGROUND:
Patients with candidemia frequently have a central venous catheter (CVC) in place, and its early removal is considered the standard of care.
METHODS:
We performed a subgroup analysis of 2 phase III, multicenter, double-blind, randomized, controlled trials of candidemia to examine the effects of early CVC removal (within 24 or 48 h after treatment initiation) on the outcomes of 842 patients with candidemia. Inclusion criteria were candidemia, age >16 years, CVC at diagnosis, and receipt of 1 dose of the study drug. Six outcomes were evaluated: treatment success, rates of persistent and recurrent candidemia, time to mycological eradication, and survival at 28 and 42 days. Univariate and multivariate analyses were performed, controlling for potential confounders.
RESULTS:
In univariate analysis, early CVC removal did not improve time to mycological eradication or rates of persistent or recurrent candidemia but was associated with better treatment success and survival. These benefits were lost in multivariate analysis, which failed to show any beneficial effect of early CVC removal on all 6 outcomes and identified Acute Physiology and Chronic Health Evaluation II score, older age, and persistent neutropenia as the most significant variables. Our findings were consistent across all outcomes and time points (removal within 24 or 48 h and survival at 28 and 42 days). The median time to eradication of candidemia was similar between the 2 study groups.
CONCLUSIONS:
In this cohort of 842 adults with candidemia followed up prospectively, early CVC removal was not associated with any clinical benefit. These findings suggest an evidence-based re-evaluation of current treatment recommendations.
AuthorsMarcio Nucci, Elias Anaissie, Robert F Betts, Bertrand F Dupont, Chunzhang Wu, Donald N Buell, Laura Kovanda, Olivier Lortholary
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 51 Issue 3 Pg. 295-303 (Aug 01 2010) ISSN: 1537-6591 [Electronic] United States
PMID20578829 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antifungal Agents (therapeutic use)
  • Blood (microbiology)
  • Candidiasis (drug therapy, therapy)
  • Catheter-Related Infections (drug therapy, therapy)
  • Double-Blind Method
  • Female
  • Fungemia (drug therapy, therapy)
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: